Y-mAbs Therapeutics (YMAB) News Today

→ The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad)

$12.28

-0.59 (-4.58%)

(As of 05/10/2024 ET)

Source

Source	Headline
	Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Down 6.8% marketbeat.com - May 10 at 9:19 PM
	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript finance.yahoo.com - May 9 at 5:50 PM
	Y-mAbs: There's A Ceiling Here Somewhere seekingalpha.com - May 9 at 9:56 AM
	Y-mAbs Therapeutics Inc (YMAB) Q1 2024 Earnings Call Transcript Highlights: Navigating ... finance.yahoo.com - May 9 at 6:35 AM
	Q1 2024 Y-mAbs Therapeutics Inc Earnings Call finance.yahoo.com - May 9 at 1:35 AM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $17.21 marketbeat.com - May 8 at 3:54 PM
	Buy Rating Affirmed for Y-Mabs Therapeutics Amid Strong Danyelza Sales and Promising SADA Radiotherapy Platform markets.businessinsider.com - May 8 at 3:34 PM
	YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024 investorplace.com - May 7 at 11:03 PM
	Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments tmcnet.com - May 7 at 7:33 PM
	Y-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue Estimates finance.yahoo.com - May 7 at 7:33 PM
	43,700 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Bought by Sapient Capital LLC marketbeat.com - May 7 at 8:57 AM
	Y-mAbs Therapeutics (YMAB) Scheduled to Post Earnings on Tuesday americanbankingnews.com - May 5 at 5:52 AM
	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Hold" by Brokerages americanbankingnews.com - May 5 at 1:44 AM
	Y-mAbs Therapeutics (YMAB) Set to Announce Quarterly Earnings on Tuesday marketbeat.com - April 30 at 1:06 PM
	Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024 globenewswire.com - April 26 at 7:05 AM
	Y-mAbs to Present at 2024 ASCO Annual Meeting globenewswire.com - April 25 at 4:05 PM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 7% marketbeat.com - April 23 at 4:47 PM
	Y-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161% finance.yahoo.com - April 18 at 1:21 PM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 4% marketbeat.com - April 11 at 11:58 AM
	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Hold" by Analysts marketbeat.com - April 10 at 2:30 AM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Down 3.3% marketbeat.com - April 9 at 11:46 AM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 3.2% marketbeat.com - April 3 at 3:27 PM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $16.19 marketbeat.com - April 2 at 11:19 AM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 5.9% marketbeat.com - April 1 at 2:01 PM
	Denali Advisors LLC Sells 69,500 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) marketbeat.com - April 1 at 6:12 AM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 3.9% marketbeat.com - March 26 at 12:38 PM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 4.3% marketbeat.com - March 19 at 11:57 AM
	Y-mAbs Therapeutics Finance Chief Bo Kruse Resigns marketwatch.com - March 15 at 8:31 AM
	Y-mAbs Therapeutics, Inc.: Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer finanznachrichten.de - March 14 at 2:58 PM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $15.84 marketbeat.com - March 14 at 11:56 AM
	Y-mAbs Therapeutics CFO Bo Kruse To Retire markets.businessinsider.com - March 14 at 9:57 AM
	Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer globenewswire.com - March 14 at 9:05 AM
	GSA Capital Partners LLP Acquires 92,765 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) marketbeat.com - March 13 at 5:32 AM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Down 8.3% marketbeat.com - March 11 at 11:52 AM
	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Holdings Raised by Trexquant Investment LP marketbeat.com - March 11 at 5:14 AM
	Cracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeutics markets.businessinsider.com - March 6 at 6:21 PM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 8.2% Following Analyst Upgrade marketbeat.com - March 6 at 11:45 AM
	HC Wainwright Raises Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $22.00 marketbeat.com - March 6 at 8:25 AM
	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 4 at 1:15 PM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Raised to $26.00 at Canaccord Genuity Group marketbeat.com - March 4 at 10:25 AM
	Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors globenewswire.com - March 4 at 7:30 AM
	Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors globenewswire.com - March 4 at 7:30 AM
	Y-mAbs Therapeutics Full Year 2023 Earnings: Beats Expectations finance.yahoo.com - March 3 at 2:52 PM
	Q4 2023 Y-mAbs Therapeutics Inc Earnings Call finance.yahoo.com - March 2 at 1:35 AM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Sets New 1-Year High at $20.90 marketbeat.com - March 1 at 10:37 AM
	Y-mAbs Therapeutics, Inc.: Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments finanznachrichten.de - March 1 at 10:34 AM
	Y-mAbs up 17% after hours on strong 2024 guidance, quarterly beats msn.com - February 29 at 6:39 PM
	Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth in Q4 and Full Year 2023 finance.yahoo.com - February 29 at 6:39 PM
	Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments globenewswire.com - February 29 at 4:05 PM
	Y-mAbs Therapeutics FY 2023 Earnings Preview msn.com - February 28 at 6:15 PM

Get Y-mAbs Therapeutics News Delivered to You Automatically

Obama’s Forever Term [exposed] (Ad)

America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.

Start streaming it now at no cost here

YMAB Media Mentions By Week

YMAB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

YMAB
News Sentiment
▼
0.23

0.58
▲
Average
Medical
News Sentiment

YMAB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

YMAB Articles
This Week
▼
16

2
▲
YMAB Articles
Average Week

Get Y-mAbs Therapeutics News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:YMAB) was last updated on 5/11/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Y-mAbs Therapeutics (YMAB) News Today

YMAB Media Mentions By Week

YMAB Media Sentiment

YMAB News Coverage

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info